Weight Change in Schizophrenia: Weight Task Force Presentation

Bruce J. Kinon, M.D.

December 1, 2003
Interindividual Variability in Weight Gain in 2 Studies in Patients With Schizophrenia

Mean Weight Change for OLZ and HAL
HGAJ: 6 Weeks

Mean Weight Change for OLZ and RIS
HGBG: 6 Weeks

Predictors of Weight Gain in Decreasing Order of Importance

- Olanzapine-Haloperidol Comparison
  - 1. OLZ vs HAL*
  - 2. Increased appetite vs normal appetite*
  - 3. Non-Caucasian vs Caucasian*
  - 4. Low vs high BBMI*
  - 5. Male vs female*
  - 6. Better vs poorer outcome*
  - 7. Young vs old
  - 8. High vs low dose

- Olanzapine-Risperidone Comparison
  - 1. Better vs poorer outcome
  - 2. Young vs old*
  - 3. Low vs high BBMI*
  - 4. Male vs female
  - 5. Non-Caucasian vs Caucasian
  - 6. Increased vs normal appetite
  - 7. OLZ vs RIS
  - 8. High vs low dose

*p<.05.
Olanzapine-Associated Weight Gain Plateaus After First 39 Weeks of Treatment

Median = 2.5 Years

Patients Observed for 39 Weeks or More; Double-blind and open-label olanzapine.

Early Identification of Patients at Risk for Substantial Weight Gain on Olanzapine*

*N=1191, LOCF.
Patients With Higher Baseline Body Mass Index (BBMI) Experienced Less Weight Gain

The Correlation Between Therapeutic Effect Size and Treatment-Emergent Weight Gain For Patients with Schizophrenia*

Therapeutic effect size as reported in Cochrane’s meta-analytical reviews\textsuperscript{23-26} of the efficacy of atypical antipsychotics compared with first generation antipsychotics. The magnitude of the typical 10-week weight gain experienced by patients treated with clozapine, olanzapine, risperidone, and haloperidol, as reported in Allison et al, 1999\textsuperscript{27}. Effect size for placebo as reported in Davis et al, 2003\textsuperscript{28}. Magnitude of placebo weight gain was obtained from the current study because typical weight gain on placebo was not previously reported.
Olanzapine Maintenance Dose Did Not Predict Weight Changes

No significant differences between mean olanzapine daily dose categories over the entire study period.

Olanzapine Weight Gain Over 1 Year

Olz = olanzapine.

Slide presented at Pfizer sponsored CME by Henry Nasrallah
Higher Baseline Body Mass Index (BBMI) Causes Less Weight Gain in Patients on Olanzapine or Risperidone

28 Weeks; Completers Only

- Low BBMI (<23 OLZ; n=30)
- Low BBMI (<23 RIS; n=23)
- High BBMI (>27 OLZ; n=41)
- High BBMI (>27 RIS; n=27)

Olanzapine Starting Dose Has No Significant Effect on Weight Gain

Effect of Starting Dose on Weight Change

- ▲ OLZ 5 mg (n=68)
- ◇ OLZ 20 mg (n=68)
- ○ PBO (n=34)

Mean Weight Gain (kg) from Baseline

0  1  2  3  4  5  6

26 weeks; observed cases

Relative Week of Therapy